Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China

Key Points

• Lorlatinib demonstrates substantial efficacy in both first-line and subsequent-line treatment settings for ALK-positive NSCLC.
• Close monitoring of lorlatinib-related adverse events can significantly enhance patient tolerance and safety during treatment.
• Incorporating lorlatinib into treatment strategies has the potential to transform outcomes for patients with ALK-positive lung cancer.
• Although the study is based on a single-center experience, the findings align with broader trends observed in cancer treatment.